Advanced Medicine

The 2025 Power List will be available soon!

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

With competition for skilled employees in cell and gene therapy manufacturing high, companies need to invest in training and mentorship.

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that?

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.